{"id":"W4399324721","doi":"10.1200/jco.2024.42.16_suppl.tps1136","title":"INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), <i>PIK3CA</i>-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Fulvestrant; Medicine; Internal medicine; Hormone receptor; Oncology; Pharmacology; Cancer; Estrogen receptor; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001321623,0.001477268,0.002135195,0.0004645911,0.0003628096,0.002124471,0.001583827,0.001659294,0.006560482],"category_scores_gemma":[0.001006742,0.0007445017,0.002048985,0.0004776455,0.0009306215,0.001030016,0.0004685071,0.004580593,0.002263605],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009729892,"about_ca_system_score_gemma":0.001702175,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00120636,"about_ca_topic_score_gemma":0.00322178,"domain_scores_codex":[0.9996867,0.0001161895,0.00001267166,0.00005911964,0.00003525596,0.00009009547],"domain_scores_gemma":[0.9993632,0.00008745517,0.0001088046,0.00005483191,0.00004162296,0.0003441346],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7251381,0.07935932,0.003348653,0.001657724,0.001905974,0.000164215,0.0003037224,0.004401787,0.03983153,0.001015583,0.01106344,0.1318099],"study_design_scores_gemma":[0.6255241,0.353502,0.006263827,0.0001352654,0.0007432047,0.0003416289,0.0001211783,0.002183877,0.003548789,0.0006395986,0.006936559,0.00005997327],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9697308,0.009007358,0.001655497,0.001143877,0.0008097393,0.004829361,0.003702874,0.0004868795,0.008633522],"genre_scores_gemma":[0.9670017,0.006209576,0.001983212,0.002214983,0.0003989998,0.004159248,0.008491689,0.0001355379,0.009405084],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006560482,"threshold_uncertainty_score":0.02194697,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03719958490996564,"score_gpt":0.424430612596551,"score_spread":0.3872310276865853,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}